

KRISHGEN BioSystems

OUR REAGENTS. YOUR RESEARCH.

BISPECIFIC ANTIBODY DRUG ELISA

FOR DRUG INTERACTION,
PHARMACO-KINETIC STUDIES AND
DEVELOPMENT OF THERAPEUTIC
DRUGS.

Developed using both binding targets as the capture and detection proteins in a sandwich assay format for specific, accurate results.

Bispecific antibodies, as the name suggests, are antibodies with two binding sites – directed against two different antigens, or in some cases, two different epitopes on the same antigen.

BsAbs have been shown to be clinically superior to monoclonal antibodies in their specificity and have a wide range of therapeutic applications under tumor and other diseases. Their clear advantage is the enhanced specificity, target-ability and reduced off-target toxicity they allow for.

More than 30 mature commercial technology platforms have been used to create and develop BsAbs based on the heterologous recombination of heavy chains and matching of light chains.

There are four main mechanisms of action of bispecific antibodies:

- Recruiting and activating of immune cells to exert killing cascade
- Blocking of dual signalling pathways
- Blocking of immune checkpoints

**LUBIO
SCIENCE**

Your distributor in Switzerland

LubioScience GmbH
Baumackerstrasse 24
8050 Zürich

+41 (0)41 417 02 80

info@lubio.ch
www.lubio.ch

**40 + DRUG
TARGETS IN A
STANDARD
96 WELL FORMAT**

All kits offer quantitative results for both serum and plasma samples. They can also be customised for other matrices.



CiteAb

THE INNOVATION AWARD

HIGHLY COMMENDED



**SPECIFIC
ANTIBODIES**



**REPRODUCIBLE
RESULTS**



**STRINGENT
VALIDATION**




**COMPETITIVE
PRICING**

WORLD'S ONLY ELISA FOR BISPECIFIC ANTIBODY DRUGS

Currently, there are seven bispecific antibodies approved by FDA and EMA, more than 180 BsAbs are in preclinical development, and over 50 BsAbs have been investigated in clinical trials.

From the concept phase to clinical trials, many companies around the world are accelerating their research and development processes of these drugs, especially CD3-targeting bsAbs. This means that quality control of bsAb drugs becomes even more critical, especially as a novel immunotherapeutic.

Krishgen offers a range of ELISA to quantify bispecific antibody drug levels accurately and quickly in serum and plasma samples.



KBI1751	KRIBIOLISA™ Acapatamab ELISA
KBI1752	KRIBIOLISA™ Alnuctamab ELISA
KBI1130	KRIBIOLISA™ Amivantamab ELISA
KBI1197	KRIBIOLISA™ Binatumomab ELISA
KBI1222	KRIBIOLISA™ Catumaxomab ELISA
KBI1753	KRIBIOLISA™ Cevostamab ELISA
KBI1231	KRIBIOLISA™ Cibisatamab ELISA
KBI1754	KRIBIOLISA™ Cinrebafusp alfa ELISA
KBI1755	KRIBIOLISA™ Duvortuzumab ELISA
KBI1756	KRIBIOLISA™ Elranatamab ELISA
KBI1757	KRIBIOLISA™ Eluvixtamab ELISA
KBI1758	KRIBIOLISA™ Emerfetamab ELISA
KBI1297	KRIBIOLISA™ Emicizumab ELISA
KBI1310	KRIBIOLISA™ Epcoritamab ELISA
KBI1317	KRIBIOLISA™ Ertumaxomab ELISA
KBI1759	KRIBIOLISA™ Etevritamab ELISA
KBI1326	KRIBIOLISA™ Faricimab ELISA
KBI1337	KRIBIOLISA™ Flotetuzumab ELISA
KBI1366	KRIBIOLISA™ Glofitamab ELISA
KBI1760	KRIBIOLISA™ Gresonitamab ELISA
KBI1761	KRIBIOLISA™ Ivicentamab ELISA
KBI1478	KRIBIOLISA™ Mosunetuzumab ELISA

KBI1492	KRIBIOLISA™ Navicixizumab ELISA
KBI1762	KRIBIOLISA™ Nivatrotamab ELISA
KBI1763	KRIBIOLISA™ Obrindatamab ELISA
KBI1764	KRIBIOLISA™ Odronextamab ELISA
KBI1765	KRIBIOLISA™ Pacanalotamab ELISA
KBI1546	KRIBIOLISA™ Pasotuzumab ELISA
KBI1766	KRIBIOLISA™ Pavurutamab ELISA
KBI1559	KRIBIOLISA™ Plamotamab ELISA
KBI1766	KRIBIOLISA™ Runimotamab ELISA
KBI1767	KRIBIOLISA™ Solitomab ELISA
KBI1768	KRIBIOLISA™ Talquetamab ELISA
KBI1769	KRIBIOLISA™ Tarlatamab ELISA
KBI1667	KRIBIOLISA™ Teclistamab ELISA
KBI1770	KRIBIOLISA™ Tepoditamab ELISA
KBI1682	KRIBIOLISA™ Tidutamab ELISA
KBI1771	KRIBIOLISA™ Ubamatamab ELISA
KBI1772	KRIBIOLISA™ Vepsitamab ELISA
KBI1773	KRIBIOLISA™ Vibecotamab ELISA
KBI1774	KRIBIOLISA™ Vixtimotamab ELISA
KBI1775	KRIBIOLISA™ Voxalatamab ELISA
KBI1745	KRIBIOLISA™ Zanidatamab ELISA
KBI1748	KRIBIOLISA™ Zenocutuzumab ELISA